Assignee
TIBOTEC PHARM LTD
IE·48 granted patents·9 pending applications·325 citations·filing 2000–2014
Top patents by PatentIndex Score
57 records- 0196US8030318B2Fused bicyclic inhibitors of HCVTIBOTEC PHARM LTD·Filed 2006·Granted Oct 4, 2011·31 cites·3 claims
- 0296US7531548B2HIV inhibiting 5-carbo- or heterocyclic substituted pyrimidinesTIBOTEC PHARM LTD·Filed 2005·Granted May 12, 2009·62 cites·18 claims
- 0393US8022077B2Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereofTIBOTEC PHARM LTD·Filed 2006·Granted Sep 20, 2011·31 cites·22 claims
- 0492US8349869B2Macrocylic inhibitors of hepatitis C virusTIBOTEC PHARM LTD·Filed 2012·Granted Jan 8, 2013·15 cites·30 claims
- 0588US7700645B2Pseudopolymorphic forms of a HIV protease inhibitorTIBOTEC PHARM LTD·Filed 2003·Granted Apr 20, 2010·30 cites·8 claims
- 0686US7659245B2Macrocylic inhibitors of hepatitis C virusTIBOTEC PHARM LTD·Filed 2006·Granted Feb 9, 2010·15 cites·28 claims
- 0785US7989471B2Macrocyclic inhibitors of hepatitis C virusTIBOTEC PHARM LTD·Filed 2006·Granted Aug 2, 2011·10 cites·16 claims
- 0884US6649651B1Hexahydrofuro[2,3-B]furan-3-yl-n{3[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-benzyl-2-hydroxypropyl}carbamate as retroviral protease inhibitorTIBOTEC PHARM LTD·Filed 2000·Granted Nov 18, 2003·18 cites·17 claims
- 0983US7666834B2Macrocyclic inhibitors of hepatitis C virusTIBOTEC PHARM LTD·Filed 2006·Granted Feb 23, 2010·10 cites·12 claims
- 1081US7217506B2Mutational profiles in HIV-1 protease correlated with phenotypic protease inhibitor resistanceTIBOTEC PHARM LTD·Filed 2003·Granted May 15, 2007·9 cites·4 claims
- 1180US9290502B2Pteridines useful as HCV inhibitors and methods for the preparation thereofTIBOTEC PHARM LTD·Filed 2013·Granted Mar 22, 2016·3 cites·12 claims
- 1279US8741926B2Macrocyclic inhibitors of hepatitis C virusTIBOTEC PHARM LTD·Filed 2012·Granted Jun 3, 2014·2 cites·19 claims
- 1379US7465727B2(1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo[1,5-c][1,3]Benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitorsTIBOTEC PHARM LTD·Filed 2006·Granted Dec 16, 2008·3 cites·5 claims
- 1479US7442705B2HIV replication inhibiting pyrimidines and triazinesTIBOTEC PHARM LTD·Filed 2004·Granted Oct 28, 2008·12 cites·11 claims
- 1579US7306901B2Methods and means for assessing HIV envelope inhibitor therapyTIBOTEC PHARM LTD·Filed 2002·Granted Dec 11, 2007·8 cites·5 claims
- 1676US8357687B2Macrocyclic indole derivatives useful as hepatitis C virus inhibitorsTIBOTEC PHARM LTD·Filed 2009·Granted Jan 22, 2013·2 cites·10 claims
- 1776US8034835B21-[[2-amino-3-(substituted alkyl)-3H-benzimidazolyl[methyl]-3-substituted-1,3-dihydro-benzoimidazol-2-ones and structural analogsTIBOTEC PHARM LTD·Filed 2006·Granted Oct 11, 2011·3 cites·13 claims
- 1876US7745432B2(1,10b-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo[1,5 C][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitorsTIBOTEC PHARM LTD·Filed 2008·Granted Jun 29, 2010·2 cites·4 claims
- 1975US7199148B2Broadspectrum substituted oxindole sulfonamide HIV protease inhibitorsTIBOTEC PHARM LTD·Filed 2003·Granted Apr 3, 2007·8 cites·15 claims
- 2073US7595408B2Methods for the preparation of (3R,3aS,6aR) hexahydro-furo[2,3-b]furan-3-olTIBOTEC PHARM LTD·Filed 2005·Granted Sep 29, 2009·2 cites·20 claims
- 2172US7449463B2Morpholinyl containing benzimidazoles as inhibitors of respiratory syncytial virus replicationTIBOTEC PHARM LTD·Filed 2004·Granted Nov 11, 2008·6 cites·36 claims
- 2272US7126015B2Method for the preparation of hexahydro-furo-[2,3-b]furan-3-olTIBOTEC PHARM LTD·Filed 2002·Granted Oct 24, 2006·5 cites·25 claims
- 2372US7087373B2Methods for determining plasma free drug concentration by direct measurement of binding affinity of protease inhibitors to plasma proteinsTIBOTEC PHARM LTD·Filed 2002·Granted Aug 8, 2006·8 cites·3 claims
- 2471US7935710B2Microbicidal pyrimidine or triazine for preventing sexual HIV transmissionTIBOTEC PHARM LTD·Filed 2003·Granted May 3, 2011·8 cites·19 claims
- 2571US7244752B2Broadspectrum 2-(substituted-amino)-benzoxazole sulfonamide HIV protease inhibitorsTIBOTEC PHARM LTD·Filed 2002·Granted Jul 17, 2007·5 cites·25 claims
- 2670US8008251B2Macrocyclic inhibitors of hepatitis C virusTIBOTEC PHARM LTD·Filed 2006·Granted Aug 30, 2011·1 cites·15 claims
- 2770US7863306B2Broadspectrum 2-amino-benzoxazole sulfonamide HIV protease inhibitorsTIBOTEC PHARM LTD·Filed 2009·Granted Jan 4, 2011·0 cites·1 claims
- 2870US7772411B2Process for the preparation of (3R,3aS,6aR)-hexahydrofuro [2,3-b] furan-3-yl (1S,2R)-3[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamateTIBOTEC PHARM LTD·Filed 2004·Granted Aug 10, 2010·7 cites·18 claims
- 2967US7615639B21-pyridyl-benzofuro[3,2-b]pyridin-2(1H)-onesTIBOTEC PHARM LTD·Filed 2005·Granted Nov 10, 2009·1 cites·18 claims
- 3064US8754106B2Macrocyclic inhibitors of hepatitis C virusTIBOTEC PHARM LTD·Filed 2013·Granted Jun 17, 2014·0 cites·34 claims
- 3160US7659404B2Broad spectrum 2-(substituted-amino)-benzothiazole sulfonamide HIV protease inhibitorsTIBOTEC PHARM LTD·Filed 2002·Granted Feb 9, 2010·1 cites·2 claims
- 3259US2010173282A1Mutational profile in hiv-1 gag cleavage site correlated with phenotypic drug resistanceTIBOTEC PHARM LTD·Filed 2008·Application pending·0 cites
- 3359US2009156595A1Pteridines useful as HCV inhibitors and methods for the preparation thereofTIBOTEC PHARM LTD·Filed 2006·Application pending·0 cites
- 3458US8036861B2Method and means for determining the replication rate of a viral populationTIBOTEC PHARM LTD·Filed 2006·Granted Oct 11, 2011·2 cites·12 claims
- 3556US7355051B2Piperdine-amino-benzimidazole derivatives as inhibitors of respiratory syncytial virus replicationTIBOTEC PHARM LTD·Filed 2004·Granted Apr 8, 2008·0 cites·8 claims
- 3656US7320878B2Protease assay for therapeutic drug monitoringTIBOTEC PHARM LTD·Filed 2002·Granted Jan 22, 2008·3 cites·16 claims
- 3756US2015010637A1Aqueous Suspensions of TMC278TIBOTEC PHARM LTD·Filed 2014·Application pending·0 cites
- 3855US7608726B2Substituted indolepyridinium as anti-infective compoundsTIBOTEC PHARM LTD·Filed 2003·Granted Oct 27, 2009·1 cites·17 claims
- 3954US7595334B2Broadspectrum 2-(substituted-amino)-benzoxazole sulfonamide HIV protease inhibitorsTIBOTEC PHARM LTD·Filed 2007·Granted Sep 29, 2009·0 cites·17 claims
- 4053US7935711B2HIV inhibiting 2-(4-cyanophenylamino) pyrimidine oxide derivativesTIBOTEC PHARM LTD·Filed 2006·Granted May 3, 2011·0 cites·3 claims
- 4152US2006205002A1Methods for determining plasma free drug concentration by direct measurement of binding affinity of protease inhibitors to plasma proteinsTIBOTEC PHARM LTD·Filed 2006·Application pending·0 cites
- 4252US2009197903A1Process for preparing spray dried formulation of tmc125TIBOTEC PHARM LTD·Filed 2007·Application pending·0 cites
- 4352US2010120855A1Macrocylic inhibitors of hepatitis c virusTIBOTEC PHARM LTD·Filed 2006·Application pending·0 cites
- 4449US2005267156A1Broadspectrum 2-amino-benzothiazole sulfonamide hiv protease inhibitorsTIBOTEC PHARM LTD·Filed 2003·Application pending·0 cites
- 4548US7763641B2Broadspectrum heterocyclic substituted phenyl containing sulfonamide HIV protease inhibitorsTIBOTEC PHARM LTD·Filed 2002·Granted Jul 27, 2010·1 cites·22 claims
- 4648US7622490B2Broadspecturm 2-amino-benzoxazole sulfonamide HIV protease inhibitorsTIBOTEC PHARM LTD·Filed 2002·Granted Nov 24, 2009·0 cites·28 claims
- 4748US7622581B26,7,8,9-substituted 1-phenyl-1,5-dihydro-pyrido[3,2-b]indol-2-ones useful as anti-infective pharmaceutical agentsTIBOTEC PHARM LTD·Filed 2005·Granted Nov 24, 2009·0 cites·9 claims
- 4848US2011165093A1Microbicidal pyrimidine or triazine for preventing sexual hiv transmissionTIBOTEC PHARM LTD·Filed 2011·Application pending·0 cites
- 4945US7994187B2HIV inhibiting 3,4-dihydro-imidazo[4,5-B]pyridin-5-onesTIBOTEC PHARM LTD·Filed 2007·Granted Aug 9, 2011·0 cites·11 claims
- 5045US7803836B2Aminophenylsulfonamide derivatives as HIV protease inhibitorTIBOTEC PHARM LTD·Filed 2006·Granted Sep 28, 2010·0 cites·6 claims
Showing the top 50 of 57 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →